Evidence map›Paper›PMID 39190702›Full record

ArticlePloS one2024

Implementing routine collection of EQ-5D-5L in a breast cancer outpatient clinic.

Sofia Torres, Ahmed M Bayoumi, Ana B K Abrahao, Maureen Trudeau, Kathleen I Pritchard, Chun Nim Li, Nicholas Mitsakakis, Geoffrey Liu, Murray Krahn

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Health related quality of life of patients with breast cancer in Malaysia: evidence from EQ-5D-5L and EORTC QLQ-C30.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sofia TorresInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-6108-6918
Ahmed M BayoumiInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Ana B K AbrahaoHospital Samaritano Higienopolis-Oncologia Américas, São Paulo, Brazil.
Maureen TrudeauDepartment of Medical Oncology, Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Kathleen I PritchardSunnybrook Research Institute, Toronto, Ontario, Canada.
Chun Nim LiSunnybrook Research Institute, Toronto, Ontario, Canada.
Nicholas MitsakakisChildren's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.
Geoffrey LiuDepartment of Medicine, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.
Murray KrahnInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA cross-sectional study was conducted to investigate the feasibility of implementing routine collection of the Euro-Qol 5 dimensions (EQ-5D) questionnaire, to inform drug and health technology reimbursement decision making.

methodsWomen with breast cancer were recruited during scheduled clinic visits to an academic cancer centre. EQ-5D-5L was self-administered using electronic tablets. Diagnostic and treatment data were abstracted from patient charts. Feasibility was assessed primarily by the proportion of patients who fully completed EQ-5D-5L and by their willingness to complete the instrument at each clinic visit.

results588 women were approached for study participation, 341 were enrolled. Fully completed EQ-5D-5L questionnaires were obtained in 323 participants (95% of participants, 95% CI 92-97%). Median time for EQ-5D-5L completion was 1.5 minutes (range:0.35 to 14.7). Mean age of participants was 58 years old. Most women who completed EQ-5D were White, born outside Canada and presented a high education level; one-quarter had metastatic disease. Most participants reported "No problems" in all EQ-5D-5L dimensions. Mean EQ-5D-5L index and mean EQ-5D-5L VAS values for all participants were respectively 0.83 (SD 0.13) and 75.7 (SD 17.45), with patients with metastatic disease scoring the lowest values. Seventy-eight percent of participants were willing to complete EQ-5D-5L at each clinic visit; lower Charlson comorbidity index and higher education level were predictors of willingness to continue to answer EQ-5D-5L.

conclusionsTablet-based collection of EQ-5D-5L in the context of routine clinical practice proved to be feasible. However, many patients declined study participation or reported being in full health, raising concerns about whether this method of collecting EQ-5D adequately represents the health status of all breast cancer patients.

Indexed as

Ambulatory Care FacilitiesBreast NeoplasmsQuality of LifeAdultAgedCross-Sectional StudiesFemaleHumansMiddle AgedSurveys and Questionnaires

Identifiers

PMID39190702
PMCPMC11349211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.